Reproductive · In Clinical Trials
Corifollitropin Alfa (Elonva)
No lawful US pathway
01 · Overview
Corifollitropin alfa is a long-acting recombinant FSH analogue created by fusing the C-terminal peptide of the hCG beta subunit to the FSH beta chain. In healthy pituitary-suppressed women, a single subcutaneous dose produced peak serum levels at 36 to 48 hours with a half-life of about 60 to 75 hours and induced follicular growth, which is the basis for one injection replacing the first week of daily FSH (PMID 12151425).
It is marketed in Europe and other regions as Elonva for controlled ovarian stimulation, but it is not listed in the FDA drug approval database and is not approved in the United States.
02 · Research summary & key findings
A Cochrane review of randomized trials comparing long-acting FSH with daily FSH found no evidence of a difference in live birth rate or in ovarian hyperstimulation syndrome at medium doses, while lower doses were associated with a reduced live birth rate (PMID 26171903). The main documented benefit is a reduced injection burden rather than improved pregnancy outcomes (PMID 26171903). Development continues, with a phase 3 trial of a corifollitropin alfa product in Chinese women reported in 2026 (PMID 42462332) and further studies registered on ClinicalTrials.gov. The earlier statement of a 2014 FDA approval was incorrect.
03 · Regulatory status
Corifollitropin Alfa (Elonva) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Corifollitropin Alfa (Elonva) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 9 FDA-approved compounds in Reproductive
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Corifollitropin Alfa (Elonva) is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females Hum Reprod, 2002. PMID 12151425
- [2]Long-acting FSH versus daily FSH for women undergoing assisted reproduction Cochrane Database Syst Rev, 2015. PMID 26171903
- [3]Corifollitropin alfa N02 versus recombinant FSH for ovarian stimulation: a phase 3 trial and safety study in Chinese women Reprod Biomed Online, 2026. PMID 42462332
Primary literature
- PubMed: "Corifollitropin Alfa"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Corifollitropin Alfa"
Registered interventional and observational studies, including status and phase.
- PubChem: "Corifollitropin Alfa"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Reproductive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.